- About Us
- Nano-Social Network
- Nano Consulting
- My Account
American Health Associates Clinical Laboratories is Accepting Patient Samples in the United States
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) are pleased to announce that AHA is accepting blood samples from across the U.S. for Nanobac's NB2 test.
"There has been a continuous, significant and strong demand for our NB2 test since we made our announcement in September that AHA would provide testing services for the Company's NB2 diagnostic test in the fourth quarter," commented Dr. Benedict Maniscalco, Chief Medical Officer, Nanobac Pharmaceuticals. "We are pleased that AHA is now accepting specimens, which is in line with our business strategy announced on our August investor conference call."
About Nanobac Pharmaceuticals Inc.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .
American Health Associates is headquartered in Miramar, Florida. For information on AHA, and how to access the NB2 testing, visit their website at http://www.americanhealthassociates.com .
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
For more information, please click here
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
Jens Dalsgaard, 415-884-0348
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
NUS researchers achieve major breakthrough in flexible electronics: New classes of printable electrically conducting polymer materials make better electrodes for plastic electronics and advanced semiconductor devices January 14th, 2017
Manchester scientists tie the tightest knot ever achieved January 13th, 2017